Seeking Alpha

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

The Company reports results of a double-blinded, randomized, placebo-controlled study, known as “MissionEB,” investigating CORDStrom for treatment of RDEB in pediatric patients, which evidence a ...
Pharmabiz

INmune Bio to submit BLA with US FDA seeking approval of CORDStrom to treat recessive dystrophic epidermolysis bullosa in paediatric patients

INmune Bio, Inc, a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has announced the following a ...
Nasdaq

BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments

BOSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 study of ...
Business Insider

BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic ...

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Phoenix Tissue Repair today announced that the first patient has been dosed in a Phase 2 study of BBP-589 ...
BioWorld

Horama lines up gene therapy trial in recessive form of retinitis pigmentosa

BioWorld - Friday, July 19, 2024 See today's BioWorld Home » Horama lines up gene therapy trial in recessive form of retinitis pigmentosa ...
BioWorld

TMPRSS3 gene therapy prolongedly restores hearing in mouse model of human recessive deafness DFNB8

Currently, there are no treatments to reverse or prevent genetic hearing loss, which affects 1 in 500 newborns. Several gene replacement and overexpression preclinical studies targeting genetic ...